A Phase II Study Of Alternating Chemoradiotherapy For Nasopharyngeal Cancer Using Cisplatin And 5-Fluorouracil
- Determine progression-free survival of patients with previously untreated stage IIB-IVB
nasopharyngeal cancer treated with fluorouracil, cisplatin, and radiotherapy.
- Determine overall survival and response rate in patients treated with this regimen.
- Determine compliance to this regimen in these patients.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive chemotherapy comprising fluorouracil IV continuously on days 1-5 and
cisplatin IV continuously on days 6-7. Beginning 2-3 days after the completion of
chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 4 weeks. With 2-3
days between each course, patients receive a second course of chemotherapy, undergo a second
course of radiotherapy, and then receive a third course of chemotherapy. Treatment continues
in the absence of unacceptable toxicity or disease progression.
Patients are followed for 3 years.
PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 2 years.
Masking: Open Label, Primary Purpose: Treatment
Progression-free survival at 3 years
Aichi Cancer Center
United States: Federal Government